Hemoglobin predicts long-term survival in dialysis patients: A 15-year single-center
longitudinal study and a correlation trend between prealbumin and hemoglobin …

Large observational population-based studies continue to demonstrate the association of
low hemoglobin with adverse outcomes, and randomized control trials fail to show a benefit …

Randomized controlled trials have consistently demonstrated adverse outcomes from
targeting higher haemoglobin levels in chronic kidney disease patients treated with …

Background: Anemia is extremely common among dialysis patients and underlies some of
the symptoms associated with reduced kidney function, including fatigue, depression …

Background Guidelines for the management of anaemia in patients with chronic kidney
disease (CKD) recommend a minimal haemoglobin (Hb) target of 11 g/dL. Recent surveys …

Background The UK Renal Association (RA) and National Institute for Health and Clinical
Excellence (NICE) have published Clinical Practice Guidelines which include …

Anemia management in hemodialysis patients has progressed following the introduction of
erythropoiesis‐stimulating agents (ESAs) and intravenous (IV) iron. However, maintaining a …

The Optimal Renal Anaemia Management Assessment trial prospectively examined the
impact of implementing European Best Practice Guidelines on outcomes in the management …

Abstract Background/Aims: Hemoglobin level variability in hemodialysis patients is common,
and has been associated with comorbidity, intercurrent illness, and mortality risk. We aimed …

Background Previous randomized-controlled trials have shown that targeting higher
hemoglobin (Hb) levels using high dose of ESA in non-dialysis chronic kidney disease …